Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- M-CSF? CSF? CSF? CSF-1-op Glu-37 MCSF-? ? ? MCSF? MCSF? MCSF?
- Product Overview:
Macrophage colony-stimulating factor (M-CSF) is a glycoprotein encoded by the CSF1 gene in humans that promotes the differentiation, proliferation, and function of mononuclear phagocytes, including macrophages, osteoclasts, and dendritic cells.{53771,53779} Alternative splicing of CSF1 pre-mRNA produces one full-length long isoform (M-CSF-?), an intermediate-length isoform (M-CSF-?), and a short-length isoform (M-CSF-?) that share sequence homology in the 150-amino acid receptor binding region that is required for the biological activity of M-CSF.{53772,53773} M-CSF exists as a disulfide-linked homodimer where each monomer contains four ?-helices, an antiparallel ?-sheet, and numerous glycosylation sites.{53771} M-CSF is constitutively produced by many cell types, including stromal cells, osteoclasts, fibroblasts, and macrophages, and is localized to the cell surface where it can be proteolytically cleaved to yield a secreted form.{53774,53775} Binding of M-CSF to the M-CSF receptor, which is expressed by monocytes, macrophages, osteoclasts, and dendritic cells, promotes cell differentiation, proliferation, and survival of mononuclear phagocytes and regulates bone resorption by osteoclasts.{53774,53778} Mice homozygous for Csf1op, an inactivating mutation, exhibit defects in fertility and neural development and develop osteopetrosis, a condition characterized by increased bone density.{53776} Neutralization of M-CSF with a monoclonal antibody decreases joint swelling and distortion in a mouse model of collagen-induced arthritis.{53777} Serum M-CSF levels are increased in patients with colorectal, pancreatic, prostate, or head and neck cancer.{53774} M-CSF has been used to generate bone marrow-derived macrophages with an anti-inflammatory phenotype in vitro.{53779} Cayman’s M-CSF-? (human, recombinant) protein can be used for cell-based assay applications. This protein consist of 158 amino acids, has a calculated molecular weight of 18.4 kDa, and a predicted N-terminus of Glu37 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the molecular mass of the protein is approximately 23 kDa due to apparent post-translational modifications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.